-
Healthpeak Q2 FFO as Adjusted $0.46; raises FY guidance midpoint by $0.02
Q2 net income $0.08 per share; FFO as Adjusted $0.46 per share, flat YoY.
-
Healthpeak raises FY 2026 guidance; Q1 FFO as adj $0.45, Janus Living IPO nets $880M
Net income $0.28, Nareit FFO $0.42, FFO as adjusted $0.45 per share for Q1 2026.
-
Healthpeak forms Janus Living for senior housing IPO; Q4 FFO $0.47, same-store NOI +3.9%
Planned IPO of Janus Living, a dedicated senior housing REIT, to unlock value; Healthpeak to retain ownership stake.
-
Healthpeak Q3 net loss $0.17/sh; AFFO $0.42; same-store NOI +0.9%
GAAP net loss of $117M ($0.17 diluted) vs income $85.7M ($0.12) in Q3 2024.
-
Healthpeak OP completes $500M offering of 4.750% senior notes due 2033
Aggregate principal $500M, 4.750% notes due Jan 15, 2033, semi-annual interest from Jan 15, 2026.
-
Healthpeak Q2 net income $0.05 EPS vs $0.21 YoY; FFO as Adj. $0.46 vs $0.45
Net income $0.05 diluted EPS vs $0.21 YoY; FFO as Adjusted $0.46 vs $0.45, AFFO $0.44 vs $0.40.
-
Healthpeak appoints Kelvin Moses as CFO; led $5B Physicians Realty integration
Kelvin O. Moses appointed CFO effective April 24, 2025, succeeding under succession plan.
-
Healthpeak Q1 net income $0.06/sh, FFO as Adjusted $0.46; same-store NOI up 7%
Net income $42.4M ($0.06 diluted EPS); Nareit FFO $0.45/sh, FFO as Adjusted $0.46/sh, AFFO $0.43/sh.
-
Healthpeak Q4 net income $0.01/sh; dividend raised 1.7% to $0.305; leadership shifts
Q4 net income $0.01/sh; Nareit FFO $0.44; FFO as Adj $0.46; AFFO $0.40.
-
Healthpeak Q3 FFO as Adjusted $0.45; raises FY guidance; lab leasing 733K sq ft
Net income $0.12/share; FFO as Adjusted $0.45; AFFO $0.41; same-store cash NOI growth 4.1%.
-
Healthpeak reports Q2 EPS $0.21, raises FY guidance, $1.2B YTD dispositions
Net income diluted $0.21/share in Q2 2024 vs $0.09 in Q2 2023; Nareit FFO $0.44, FFO as Adjusted $0.45, AFFO $0.39.
-
Healthpeak merger pro forma shows 2023 diluted EPS $0.22, Q1 2024 loss $0.03
Pro forma 2023 revenue $2.77B, net income $152.7M; diluted EPS $0.22.
-
Healthpeak Q1 FFO as Adjusted $0.45 beats; raises full-year guidance midpoint by $0.02
Q1 net income $0.01/sh; FFO as Adj $0.45 (vs $0.42 YoY); AFFO $0.41 (vs $0.38).
-
Healthpeak establishes $1.5B at-the-market equity offering program
Amendment to ATM equity sales agreement executed March 11, 2024, adding up to $1.5B in common stock issuance capacity.
-
Healthpeak closes Physicians Realty Trust acquisition; ticker to change to DOC
Each Physicians Realty Trust common share converted into 0.674 Healthpeak shares.
-
Physicians Realty Trust FY2023 audited financials filed; net income $43.8M, diluted EPS $0.17
Total revenues $543.5M in 2023, up from $526.6M in 2022; net income fell to $43.8M from $110.0M.
-
Healthpeak stockholders and Physicians Realty shareholders approve merger; close expected March 1
Healthpeak stockholders approved stock issuance with 456.7M for, 11.9M against.
-
Healthpeak Q4 FFO as Adj $0.46/share; Same-store NOI +3.6%; new $236M lab JV
Q4 net income $0.13/share, Nareit FFO $0.48, FFO as Adj $0.46, AFFO $0.36; FY23 net income $0.56, Nareit FFO $1.79, FFO as Adj $1.78, AFFO $1.53.
-
Physicians Realty Trust provides preliminary Q4 & FY 2023 estimates ahead of Healthpeak merger
Preliminary Q4 net income $4M-$11M ($0.02-$0.04 EPS); FFO per share $0.22-$0.24.
-
Healthpeak and Physicians Realty Trust to combine in $21B all-stock merger of equals
Each DOC share converts to 0.674 PEAK share; pro forma PEAK owns 77%, DOC 23%.
-
Healthpeak to acquire Physicians Realty Trust in all-stock merger valued at ~$6B
Each Physicians Realty share will convert into 0.674 Healthpeak shares; expected close first half of 2024.
-
Healthpeak Q3 net income $0.12/share, FFO as Adjusted $0.45; raises FY guidance
Net income $0.12 per share vs $0.65 YoY; FFO as Adjusted $0.45 (up from $0.43), AFFO $0.40 (vs $0.36).
-
Healthpeak Q2 2023 FFO as Adjusted $0.45, up $0.01 YoY; guidance raised
Net income $0.09 per diluted share (Q2 2022: $0.13); Nareit FFO $0.45; FFO as Adjusted $0.45; AFFO $0.40.
-
Healthpeak Properties raises full-year 2023 guidance at REITweek conference
Full-year 2023 guidance ranges increased as presented at Nareit REITweek 2023 investor conference on June 5, 2023.
-
Healthpeak shareholders approve 2023 equity plan (30.8M shares), re-elect board, approve say-on-pay
2023 Performance Incentive Plan approved (90.78% support); authorizes up to 30,836,601 shares, replacing 2014 Plan.
-
Healthpeak Q1 FFO $0.42/share, Same-Store NOI +5.5%, declares $0.30 dividend
Net income $0.22 diluted EPS ($117.7M); Nareit FFO $0.42; AFFO $0.38.